Table 4.
Result of base-case cost-utility analysis and hypothetical introduction of a 10% price discount
| Treatment | Total cost (US$) | QALYs | ICER | ICER vs NTZ | |
|---|---|---|---|---|---|
| Natalizumab | $218,959 | 9.519 | $0 | $0 | |
| Ocrelizumab | $241,778 | 9.912 | $58,062 | $58,062 | Extended dominated |
| Cladribine | $289,949 | 11.394 | $32,504 | $37,861 | |
| Alemtuzumab | $293,629 | 10.786 | −$6052 | $58,934 | Dominated by CLB |
| 10% price discount | |||||
| Natalizumab | $218,959 | 9.519 | $0 | $0 | |
| Ocrelizumab | $241,778 | 9.912 | $58,062 | $58,062 | Extended dominated |
| Cladribine | $274,898 | 11.394 | $22,348 | $29,833 | |
| Alemtuzumab | $293,629 | 10.786 | −$30,807 | $58,934 | Dominated by CLB |
| Sensitivity analysis: 10-year time horizon | |||||
| Alemtuzumab | $140,654 | 5.026 | $0 | $160,964 | |
| Cladribine | $153,795 | 5.212 | $70,745 | Dominant | |
| Natalizumab | $170,109 | 5.209 | −$5,907,228 | $0 | Dominated by CLB |
| Ocrelizumab | $191,421 | 5.446 | $90,125 | $90,125 | |
CLB cladribine, ICER incremental cost-effectiveness ratio, NTZ natalizumab, QALYs quality-adjusted life-years